SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

Lüscher, TF; Taddei, S; Kaski, JC; Jukema, JW; Kallend, D; Münzel, T; Kastelein, JJ; Deanfield, JE; dal-VESSEL Investigators (2012) Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J, 33 (7). 857 - 865. https://doi.org/10.1093/eurheartj/ehs019
SGUL Authors: Kaski, Juan Carlos

Full text not available from this repository.

Abstract

High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C, the first cholesterol transport protein (CETP) inhibitor torcetrapib raised blood pressure (BP), impaired endothelial function, and increased CV mortality and morbidity. Dalcetrapib is a novel molecule acting on CETP with a different chemical structure to torcetrapib. As HDL stimulates nitric oxide (NO), suppresses inflammation, and exerts protective CV effects, we investigated the effects of dalcetrapib on endothelial function, blood pressure, inflammatory markers, and lipids in patients with, or at risk of, coronary heart disease (CHD) in a double-blind randomized placebo-controlled trial (clinicaltrials.gov number NCT00655538).

Item Type: Article
Additional Information: PMCID: PMC3345558
Keywords: Aged, Anticholesteremic Agents, Biological Markers, Blood Flow Velocity, Blood Pressure, Brachial Artery, Cholesterol Ester Transfer Proteins, Cholesterol, HDL, Cholesterol, LDL, Coronary Disease, Double-Blind Method, Endothelium, Vascular, Female, Humans, Hypercholesterolemia, Male, Middle Aged, Sulfhydryl Compounds, Treatment Outcome, Triglycerides, Vasodilation
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Eur Heart J
Dates:
DateEvent
April 2012Published
PubMed ID: 22345126
Web of Science ID: 22345126
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/101239
Publisher's version: https://doi.org/10.1093/eurheartj/ehs019

Actions (login required)

Edit Item Edit Item